Fulcrum Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Fulcrum Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Fulcrum Therapeutics Inc
Rating: 1.36425
Author: Trendlyne DVM scores

about

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) ...

7.68 0.05 (0.66%)

51.21% Fall from 52W High

27,475.5

XNAS Volume

XNAS 13 Mar, 2026 9:51 AM (EDT)

Not Eligible

Expensive Valuation

12.0 / 100

Technically Neutral

42.6 / 100

1Yr Price target upside is 147%

10 analysts

Fulcrum Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Fulcrum Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) ...

51.21% Fall from 52W High

SWOT Analysis

Fulcrum Therapeutics Inc Live Price Chart